543 related articles for article (PubMed ID: 19041685)
41. Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factor beta 1 in human hepatocellular carcinoma cells.
Miyazaki M; Sakaguchi M; Akiyama I; Sakaguchi Y; Nagamori S; Huh NH
Cancer Res; 2004 Jun; 64(12):4155-61. PubMed ID: 15205326
[TBL] [Abstract][Full Text] [Related]
42. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
43. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
44. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
[TBL] [Abstract][Full Text] [Related]
45. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells.
Marchal JA; Núñez MC; Suárez I; Díaz-Gavilán M; Gómez-Vidal JA; Boulaiz H; Rodríguez-Serrano F; Gallo MA; Espinosa A; Aránega A; Campos JM
Breast Cancer Res Treat; 2007 Nov; 105(3):237-46. PubMed ID: 17124554
[TBL] [Abstract][Full Text] [Related]
46. Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate.
Wang CT; Meng M; Zhang JC; Jin CJ; Jiang JJ; Ren HS; Jiang JM; Qin CY; Yu DQ
Chin Med J (Engl); 2008 Sep; 121(17):1707-11. PubMed ID: 19024104
[TBL] [Abstract][Full Text] [Related]
47. Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2.
Tsukada Y; Tanaka T; Miyazawa K; Kitamura N
J Biochem; 2004 Nov; 136(5):701-9. PubMed ID: 15632311
[TBL] [Abstract][Full Text] [Related]
48. 7,8-dihydroxyflavone induces G1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation.
Park HY; Kim GY; Hyun JW; Kim ND; Kim CG; Kim WJ; Yoo YH; Choi YH
Oncol Rep; 2012 Jul; 28(1):353-7. PubMed ID: 22552501
[TBL] [Abstract][Full Text] [Related]
49. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
[TBL] [Abstract][Full Text] [Related]
50. Induction of cell cycle arrest via the p21, p27-cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol.
Huang Z; Wang L; Chen L; Zhang Y; Shi P
Acta Pharm; 2015 Dec; 65(4):463-71. PubMed ID: 26677902
[TBL] [Abstract][Full Text] [Related]
51. [Inhibitory effect of wild-type RASSF1A gene expression on proliferation of hepatocellular carcinoma QGY-7703 cells].
Rui L; Xue WJ; Li P; Wang ZW; Wang P; Li HX
Ai Zheng; 2008 Sep; 27(9):924-8. PubMed ID: 18799029
[TBL] [Abstract][Full Text] [Related]
52. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
[TBL] [Abstract][Full Text] [Related]
53. SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells.
Pang LP; Huang W; Sun Q; Guo W; Li RT; Cui JR
Anticancer Drugs; 2008 Feb; 19(2):167-74. PubMed ID: 18176113
[TBL] [Abstract][Full Text] [Related]
54. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation.
Shirako E; Hirayama N; Tsukada Y; Tanaka T; Kitamura N
J Cell Biochem; 2008 May; 104(1):176-88. PubMed ID: 18004740
[TBL] [Abstract][Full Text] [Related]
55. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
56. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis.
Sirach E; Bureau C; Péron JM; Pradayrol L; Vinel JP; Buscail L; Cordelier P
Cell Death Differ; 2007 Jun; 14(6):1202-10. PubMed ID: 17347668
[TBL] [Abstract][Full Text] [Related]
57. SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15.
Hung H; Pierce CK; Chee SK; Lawrence P; Hung NT
J Cell Physiol; 2005 Sep; 204(3):785-91. PubMed ID: 15754328
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of cell growth and induction of G1-phase cell cycle arrest in hepatoma cells by steroid extract from Meretrix meretrix.
Wu TH; Yang RL; Xie LP; Wang HZ; Chen L; Zhang S; Zhao Y; Zhang RQ
Cancer Lett; 2006 Feb; 232(2):199-205. PubMed ID: 16458116
[TBL] [Abstract][Full Text] [Related]
59. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
60. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs).
Haller F; Löbke C; Ruschhaupt M; Cameron S; Schulten HJ; Schwager S; von Heydebreck A; Gunawan B; Langer C; Ramadori G; Sültmann H; Poustka A; Korf U; Füzesi L
J Pathol; 2008 Jul; 215(3):253-62. PubMed ID: 18438954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
